UHCs 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP-2)
If the internal resistance is too high, the battery will not sustain high loads for long
GLP-1 RAs may inhibit retinal neurodegeneration and reduce proinflammatory processes, which could protect against diabetic retinopathy progression
Thinking about switching from semaglutide to tirzepatide, or vice versa